Original articleCancer incidence and mortality in France over the 1980–2012 period: Solid tumorsIncidence et mortalité des cancers en France durant la période 1980–2012 : tumeurs solides
Introduction
The availability of updated cancer incidence and mortality indicators is of paramount importance for decision-making and public health policy implementation. Such indicators allow to describe accurately the epidemiological features of cancer and their progression over time. They are used to develop and assess programs for primary prevention, screening, and care. They also provide public healthcare policy-makers with the necessary information to assess the needs of the population in terms of cancer management, prioritize prevention strategies, and evaluate therapeutic progress.
This article is a follow-up of a previous study on cancer incidence and mortality published in 2008 on the 1980–2005 period [1], [2]. This collaborative work involved the French network of cancer registries (Francim), the Department of Biostatistics of the Hospices Civils de Lyon (HCL), the Institut de veille sanitaire (InVS) and the Institut national du cancer (Inca). It is an integral part of the national cancer program (Plan Cancer 2009–2013) relating to the observation of cancer epidemiology [3].
Cancer registries provide a continuous and exhaustive recording of all cancer cases in a predefined geographical area. Thus, registry data are essential to estimate cancer incidence at a national level. The Francim network has created a common database that brings together all cancer data from participating registries, some dating back to 1975.
We report here estimates of the trends in incidence of cancer and mortality from cancer (solid tumors only) in France between 1980 and 2012. The trends in incidence of hematological malignancies will be published separately.
Section snippets
Incident cases
Data on incidence were taken from the common database of all Francim network registries. For the purposes of the present study, data from 21 registries having at least 5 years of recorded data were used (Table 1).
Among solid tumors, 19 cancer sites were analyzed. These sites were defined according to the International classification of diseases for oncology, 3rd edition (ICD-O3) [4] and are shown in Table 2. For each site, the following rules were applied: only invasive tumors were considered
Results
All details, results, and the full report (in pdf format) are available at: http://www.invs.sante.fr/fr/Dossiers-thematiques/Maladies-chroniques-et-traumatismes/Cancers/Surveillance-epidemiologique-des-cancers/Estimations-de-l-incidence-et-de-la-mortalite/Estimation-de-l-incidence-et-de-la-mortalite-par-cancer-en-France-entre-1980-et-2012-Tumeurs-solides.
Age-standardized incidence rates are essential to analyze the trends in risk, whereas the number of incident cases is necessary to make
Discussion
The present results are an update of previous publications [2], [10] based on data from a larger number of cancer registries that cover a longer period (1980–2009). The participating registries cover a population of over 8.8 million inhabitants (over 10.8 million for digestive tract cancers) and the oldest registries have been recording data for over 30 years. Although the French cancer registry network covers only 16–20% of the population (the proportion varies according to cancer site), the
Disclosure of interest
The authors declare that they have no conflicts of interest concerning this article.
Acknowledgements
The authors thank all those who contributed to the recording of cancer data in the registries, most particularly the laboratories and departments of anatomy, cytology, and pathology; the departments of medical information of the public and private hospitals; the local offices of the national social security service; and general practitioners and specialists. The authors also thank Jacques Estève for his methodological support, Fiona Ecarnot and Jean Iwaz for the translation of the original
References (42)
- et al.
Cancer incidence and mortality in France over the period 1980–2005
Rev Epidemiol Sante Publique
(2008) - et al.
Reliability of recording uterine cancer in death certification in France and age-specific proportions of deaths from cervix and corpus uteri
Cancer Epidemiol
(2011) - et al.
Âge en années révolues ou âge atteint dans l’année
Rev Epidemiol Sante Publique
(2005) - et al.
Epidemiology and risk factors for oesophageal adenocarcinoma
Dig Liver Dis
(2013) - et al.
Effects of occupational and educational changes on obesity trends in France: the results of the MONICA-France survey 1986–2006
Prev Med
(2011) - et al.
Prevalence and treatment of diabetes in France: trends between 2000 and 2005
Diabetes Metab
(2008) - et al.
L’épidémiologie des cancers en France en 2010 : comparison avec les États-Unis
Bull Cancer
(2010) - et al.
Breast cancer incidence and time trend in France from 1990 to 2007: a population-based study from two French cancer registries
Ann Oncol
(2011) - et al.
La diminution de l’utilisation du traitement hormonal de la ménopause a-t-elle fait baisser l’incidence du cancer du sein en France (et ailleurs) ?
Rev Epidemiol Sante Publique
(2008) - et al.
Prostate cancer incidence and mortality trends in 37 European countries: an overview
Eur J Cancer
(2010)
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012
Eur J Cancer
Testicular cancer in Europe and the USA: survival still rising among older patients
Ann Oncol
Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990
Eur J Cancer
Descriptive epidemiology of thyroid cancer in France: incidence, mortality and survival
Ann Endocrinol (Paris)
National cancer incidence is estimated using the incidence/mortality ratio in countries with local incidence data: is this estimation correct?
Cancer Epidemiol
Estimation nationale de l’incidence et de la mortalité par cancer en France entre 1980 et 2005
International classification of diseases for oncology
Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods
Int J Cancer
Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France
Int J Cancer
Lung cancer rate predictions using generalized additive models
Biostatistics
Cited by (175)
Cancer screening in chronic inflammatory rheumatic diseases
2023, Joint Bone SpineHead and Neck cancers induced by human Papillomavirus infection, epidemiological, diagnostic, prognostic and therapeutic specificities
2023, Bulletin de l'Academie Nationale de MedecineCancer screening in rheumatic diseases
2022, Revue du Rhumatisme MonographiesNational institutions should improve the information made available to patients about cervical smears
2021, Patient Education and Counseling